文献速递脑血管病

SWIFT PRIME 试验中 MRI 与 CTP 选择患者对支架取栓疗效的影响

Efficacy of Stent-Retriever Thrombectomy in Magnetic Resonance Imaging Versus Computed Tomographic Perfusion-Selected Patients in SWIFT PRIME Trial (Solitaire FR With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke).
PubMed 文献 · Stroke · 2017-05-02

SWIFT PRIME 试验比较了 MRI 与 CTP 选择患者后支架取栓的疗效。MRI 组 34 例,CTP 组 139 例,两组基线 NIHSS 均为 17,目标错配比例分别为 95% 与 83%。MRI 组发病至随机化时间更长,但急诊到随机化时间无差异,两组 90 天 mRS 均显示显著获益(MRI P=0.02,CTP P=0.01),梗死体积增长均减少,血管内治疗获益相似。

要点

  • MRI 选择患者发病至随机化时间更长,但院内延误未增加。
  • 两组支架取栓均显著改善 90 天 mRS,获益相似。
  • MRI 与 CTP 选择均有效,临床可依据实际条件选择。

核心结论

  • MRI 选择患者发病至随机化时间显著长于 CTP,但两组血管内治疗获益相似。

研究设计与样本

  • SWIFT PRIME 试验的亚组分析,比较 MRI 选择(34 例)与 CTP 选择(139 例)患者。
  • 患者为大脑中动脉及远端颈内动脉闭塞,随机接受单纯 tPA 或 tPA+支架取栓。

主要发现

  • MRI 组目标错配比例为 95%,CTP 组为 83%。
  • MRI 组从外院转运比例更高(P=0.02),发病至随机化时间更长(P=0.003)。
  • 急诊到随机化时间两组无差异,基线缺血核心体积相似。
  • 支架取栓患者再灌注率(>90%/TICI 3 级)两组无差异。
  • 主要疗效分析显示 90 天 mRS 在 MRI 组(P=0.02)和 CTP 组(P=0.01)均有显著获益。

关键数值与推荐

  • 主要结局为 90 天改良 Rankin 量表评分分布。
  • 再灌注评估采用 TICI 评分,>90% 再灌注定义为 TICI 3 级。

临床怎么用

  • MRI 选择患者不应因转运延误而排除血管内治疗,院内流程时间未延长。
  • CTP 与 MRI 均可用于筛选适合支架取栓的患者,疗效相似。

局限性

  • MRI 组样本量较小(34 例),结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The majority of patients enrolled in SWIFT PRIME trial (Solitaire FR With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke) had computed tomographic perfusion (CTP) imaging before randomization; 34 patients were randomized after magnetic resonance imaging (MRI). METHODS: Patients with middle cerebral artery and distal carotid occlusions were randomized to treatment with tPA (tissue-type plasminogen activator) alone or tPA+stentriever thrombectomy. The primary outcome was the distribution of the modified Rankin Scale score at 90 days. Patients with the target mismatch profile for enrollment were identified on MRI and CTP. RESULTS: MRI selection was performed in 34 patients; CTP in 139 patients. Baseline National Institutes of Health Stroke Scale score was 17 in both groups. Target mismatch profile was present in 95% (MRI) versus 83% (CTP). A higher percentage of the MRI group was transferred from an outside hospital (P=0.02), and therefore, the time from stroke onset to randomization was longer in the MRI group (P=0.003). Time from emergency room arrival to randomization did not differ in CTP versus MRI-selected patients. Baseline ischemic core volumes were similar in both groups. Reperfusion rates (>90%/TICI [Thrombolysis in Cerebral Infarction] score 3) did not differ in the stentriever-treated patients in the MRI versus CTP groups. The primary efficacy analysis (90-day mRS score) demonstrated a statistically significant benefit in both subgroups (MRI, P=0.02; CTP, P=0.01). Infarct growth was reduced in the stentriever-treated group in both MRI and CTP groups. CONCLUSIONS: Time to randomization was significantly longer in MRI-selected patients; however, site arrival to randomization times were not prolonged, and the benefits of endovascular therapy were similar. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01657461.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Menjot de Champfleur N, Saver JL, Goyal M, et al. Efficacy of Stent-Retriever Thrombectomy in Magnetic Resonance Imaging Versus Computed Tomographic Perfusion-Selected Patients in SWIFT PRIME Trial (Solitaire FR With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke). Stroke. 2017. PMID: 28465460. doi:10.1161/STROKEAHA.117.016669

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。